IDEXX Laboratories, Inc. (IDXX) has unveiled the IDEXX Cancer Dx, a first-of-its-kind diagnostic panel with early detection of lymphoma in dogs. This affordable and accessible blood test can be added to panels for sick pets and integrated into annual wellness screenings for as low as $15, providing veterinarians in the United States with actionable results within two to three days.The test is especially crucial for the 20 million dogs in North America who face an increased risk of cancer. Early detection an ...

Core Insights - IDEXX Laboratories, Inc. has launched IDEXX Cancer Dx™, a pioneering diagnostic panel for early detection of lymphoma in dogs, particularly targeting the 20 million dogs at higher risk for cancer in North America [1][2][3] - The test is affordable, costing as low as $15, and provides actionable results within 2–3 days, making it accessible for veterinarians [1][4] - Cancer is a leading cause of death in dogs, with 1 in 4 dogs in the U.S. expected to be diagnosed with cancer in their lifetime, highlighting the critical need for early detection [2][3] Company Overview - IDEXX is recognized as a global leader in pet healthcare innovation, with over 40 years of experience in veterinary research and technology development [3][6] - The company employs approximately 11,000 people and offers solutions in more than 175 countries, indicating a strong global presence [7] - IDEXX Cancer Dx is designed to integrate seamlessly into existing veterinary workflows, enhancing the ability of veterinarians to manage cancer proactively [6][4] Market Demand - A recent survey revealed that 73% of pet owners are interested in cancer screening tests for their pets, indicating a strong market demand for proactive healthcare solutions [2][4] - The IDEXX Cancer Dx panel aims to improve the quality of life for canine cancer patients by enabling earlier clinical diagnoses compared to traditional methods [4][5] Future Plans - IDEXX plans to expand the Cancer Dx panel over the next three years to cover a broader range of canine cancer cases, further transforming cancer detection and intervention [1][3] - The IDEXX Cancer Dx test for canine lymphoma will be available at IDEXX Reference Laboratories in the U.S. and Canada starting in late March 2025 [5][9]

IDEXX’s (IDXX) business continues to be dampened by currency impacts and uncertain macroeconomic conditions. The stock carries a Zacks Rank #4 (Sell) currently.Concerning Factors for IDXXIn recent times, U.S. clinical visit growth levels have been constrained by persistent staffing challenges at veterinary clinics and the cumulative impacts of broader macroeconomic challenges on consumers. Meanwhile, challenges in the Asia-Pacific, including the impacts of reduced swine testing in China and lower health scr ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium also includes the Zacks Style Scores. What ...

BOSTON, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Sustainability Roundtable, Inc. (SR Inc), a leader in strategic advisory and support services, proudly announces the recipients of its 2024 Sustainable Business & Enterprise Roundtable (SBER) Awards. Presented the eve before its Summit for Sustainable Business VIII: Decarbonizing Corporate Global Operations at the St. Regis hotel in Washington, D.C., these recognitions commemorate SBER's 2024 standout sustainability leaders. Award Recipients and Achievements SR Inc ...

One of my favorite ways to add money to my portfolio is to invest in proven compounders with track records of delivering market-beating results after short-term pullbacks. This idea is especially true when the stocks in question are trading at what could prove to be once-in-a-decade opportunities.Two companies that fit this description now are animal healthcare specialists Idexx Laboratories (IDXX 0.02%) and Zoetis (ZTS 0.94%). While Idexx is already one of my daughter's core holdings and Zoetis is one of ...

IDEXX Laboratories, Inc.’s (IDXX) consistent strong performance of the CAG (Companion Animal Group) segment is poised to help it grow in the upcoming quarters. Robust demand for its cloud-based offerings instills optimism, reflecting the company’s focus on improving patient care rather than back-office tasks. Solid performance in the international markets is encouraging. However, unfavorable solvency and the impact of third-party distributors remain our concerns for IDEXX’s operations. In the past year, thi ...

Trading at its most reasonable valuation since 2016, this pet healthcare diagnostics leader could be a once-in-a-decade opportunity today.While the debate over whether it's better to pay for high-quality or high-growth businesses will never end, the easiest solution is to find stocks offering both.One company that fits this best-of-both-worlds billing is Idexx Laboratories (IDXX 0.19%), offering leading pet healthcare diagnostics operations. Delivering annualized revenue and free-cash-flow growth of 10% and ...

Financial Data and Key Metrics Changes - IDEXX reported a 6% organic revenue growth in Q3 2024, with a 7% growth in CAG diagnostic recurring revenues and a 13% growth in the water business [7][10] - EPS for Q3 was $2.80, reflecting an 11% increase as reported and a 12% increase on a comparable basis [9][24] - Operating margins improved to 31.2%, up 110 basis points year-on-year [24] Business Line Data and Key Metrics Changes - CAG organic revenue growth was 6%, supported by 6% growth in veterinary software services and diagnostic imaging revenues, while LPD experienced a 2% organic decline [10][12] - CAG diagnostic recurring revenue increased 7% organically, with a 5% average global net price improvement [12][23] - Consumable revenues increased 11% organically, driven by strong gains in the US and international regions [19] Market Data and Key Metrics Changes - US CAG diagnostic recurring revenue organic growth was 5%, with a 1.5% growth benefit from equivalent days effects [14] - International growth was supported by 10% organic gains, reflecting strong new business gains and high premium instrument placements [13][22] - The US clinical visit growth was constrained by a 2.1% decline in same-store clinical visits, particularly in discretionary wellness visits [15][16] Company Strategy and Development Direction - IDEXX aims to lead the companion animal diagnostics sector through innovation and a high-touch commercial model, focusing on organic growth [33][34] - The company is on track for the launch of the IDEXX inVue Dx Cellular Analyzer in Q4, with nearly 700 pre-orders already secured [43][44] - IDEXX is expanding its corporate account relationships, which are expected to drive long-term volume growth [42][84] Management's Comments on Operating Environment and Future Outlook - Management acknowledged near-term macro pressures affecting clinical visit growth but remains confident in long-term demand drivers for diagnostics [36][62] - The updated full-year organic revenue growth outlook is now 5.3% to 6%, reflecting a reduction due to recent US macro trends [26][27] - Management emphasized the resilience of pet owners in prioritizing pet care despite broader economic pressures [62] Other Important Information - Free cash flow for Q3 was $192 million, with a net income to free cash flow conversion ratio of 91% [25] - The company maintained its outlook for free cash flow conversion of 90% to 95% for the full year [25] - IDEXX's balance sheet remains strong, with leverage ratios of 0.7 times gross and 0.4 times net of cash [26] Q&A Session Summary Question: Can you elaborate on the drivers of the reduction outlook and the step down in Q4? - Management indicated that the 3.5% to 4% growth outlook for CAGDX recurring revenue is net of an estimated 0.5% impact from hurricanes, with normalized growth expected to be 4% to 4.5% [58][59] Question: What is the biggest delta between the underlying outlook given in Q2 versus now? - Management noted that the pressure on end clinic demand was greater than anticipated, contributing to the revised outlook [59][62] Question: Can you expand on the reference lab performance and pricing dynamics? - Management reported 2.4% organic growth in reference labs, with volume growth being positive but moderated by new customer agreements affecting price realization [66][70] Question: How do you view pricing as a lever going forward? - Management confirmed a consistent 5% full-year price outlook, with some moderation expected in Q4 due to new business effects [72][73] Question: Can you discuss the impact of pain medication visits on overall visit trends? - Management clarified that while pain medication visits have increased, they do not typically include diagnostics, leading to a decline in overall diagnostic-related visits [104]

IDEXX Laboratories, Inc. (IDXX) posted third-quarter 2024 earnings per share (EPS) of $2.80, up 10.7% year over year. The figure surpassed the Zacks Consensus Estimate by 4.1%.Comparable constant-currency EPS of $2.79 improved 12% year over year.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Following the earnings announcement, IDXX stock fell 3.1% at the pre-market trading today.IDEXX’s Revenues in DetailQuarterly revenues increased 6.6% year over year (up 6% organically) to $975.5 ...